4 results
The first aim of the study is to investigate whether DCS addition to exposure therapy enhances symptom reduction in PD+AGO. The second objective of the study is to establish the optimal timing of administration of DCS (30 minutes before or directly…
To determine the safety and tolerability of L19-IL2 combined with SABR.
To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE…
The purpose of this scientific study is to verify whether immunotherapy (L19-IL2) after a standard treatment such as radiotherapy, fights the metastatic disease more efficiently than the current standard treatment alone.